Bladder cancer: open trials in Canada

42 open trials have a site in Canada. Registry data; only the trial team decides who can take part.

NCT07090499
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Trial Treatment · Phase 1 · Pfizer
McGill University Health Centre, Montreal · Princess Margaret Cancer Centre, Toronto
Registry updated 2026-11-05
NCT05614739
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Trial Treatment · Phase 1 · Eli Lilly and Company
Princess Margaret Hospital, Toronto · British Columbia Cancer Agency, Vancouver
Registry updated 2026-11-04
NCT05987241
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Trial Treatment · Phase 2/3 · National Cancer Institute (NCI)
Arthur J.E. Child Comprehensive Cancer Centre, Calgary · Cross Cancer Institute, Edmonton · Waterloo Regional Health Network, Kitchener · London Regional Cancer Program, London · Ottawa Hospital and Cancer Center-General Campus, Ottawa · Allan Blair Cancer Centre, Regina · Saskatoon Cancer Centre, Saskatoon · Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto · University Health Network, Princess Margaret Hospital, Toronto · BCCA - Vancouver Cancer Centre, Vancouver
Registry updated 2026-11-04
NCT06760819
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Trial Treatment · Phase 2 · Bayer
Queen Elizabeth II Health Sciences Centre | Oncology, Halifax · Research Institute of the McGill University Health Centre | Women Health's Research Unit, Montreal · Princess Margaret Cancer Centre | Medical Oncology and Hematology, Toronto
Registry updated 2026-11-04
NCT07419295
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC
Lakeridge Health ( Site 0122), Oshawa · Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0121), Québec · Princess Margaret Cancer Centre ( Site 0123), Toronto
Registry updated 2026-11-03
NCT07660055
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
Trial Treatment · Phase 1 · Novartis Pharmaceuticals
Montreal
Registry updated 2026-11-03
NCT07475806
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
Trial Treatment · Phase 2 · Astellas Pharma Global Development, Inc.
Toronto
Registry updated 2026-11-02
NCT06510374
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Trial Treatment · Phase 3 · Ferring Pharmaceuticals
G. Kenneth Jansz Medicine Professional Corporation, Burlington · Prostate Cancer Centre, Calgary · Research St. Joseph's- Hamilton/St. Joseph's Healthcare Hamilton, Hamilton · University Health Network UHN Princess Margaret Cancer Centre, Toronto
Registry updated 2026-10-30
NCT06545955
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Trial Treatment · Phase 3 · Ferring Pharmaceuticals
Prostate Cancer Centre, Calgary · Research St. Joseph's- Hamilton/St. Joseph's Healthcare Hamilton, Hamilton · Centre Hospitalier de l'Université de Montréal, Montreal · University Health Network UHN Princess Margaret Cancer Centre, Toronto
Registry updated 2026-10-30
NCT07144319
Exploration of Novel AI-enabled Blue Light Enhanced Cystoscopy
Research · Photocure
Vancouver Prostate Centre at Vancouver General Hospital, Vancouver
Registry updated 2026-10-29
NCT07222488
A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)
Trial Treatment · Phase 1/2 · Merck Sharp & Dohme LLC
CHU de Quebec - Hopital de l'Enfant-Jesus ( Site 0011), Québec
Registry updated 2026-10-29
NCT07566156
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Trial Treatment · Phase 3 · Astellas Pharma Global Development, Inc.
Chicoutimi · Montreal · Montreal
Registry updated 2026-10-28
NCT05327647
A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer
Trial Treatment · Phase 2 · CHU de Quebec-Universite Laval
Centre intégré de santé et services sociaux de Chaudière Appalaches, Lévis · London Health Sciences Centre, London · McGill University Health Centre_CUSM, Montreal · Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal · CHU de Quebec-Universite Laval, Québec · CIUSSS de l'Estrie-CHUS, Sherbrooke · University Health Network - Princess Margaret Cancer Centre, Toronto
Registry updated 2026-10-26
NCT06172478
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Trial Treatment · Phase 2 · Daiichi Sankyo
Cross Cancer Institute, Edmonton · Sunnybrook Research Institute, Toronto · Princess Margaret Cancer Centre, Toronto · BC Cancer - Vancouver, Vancouver
Registry updated 2026-10-26
NCT07097142
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Trial Treatment · Phase 3 · NRG Oncology
The Research Institute of the McGill University Health Centre (MUHC), Montreal
Registry updated 2026-10-23
NCT06770582
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Trial Treatment · Phase 2 · National Cancer Institute (NCI)
The Research Institute of the McGill University Health Centre (MUHC), Montreal · CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ), Québec
Registry updated 2026-10-19
NCT06960577
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
Trial Treatment · Phase 2 · AstraZeneca
Hamilton · London · Montreal · Ottawa · Québec · Sherbrooke
Registry updated 2026-10-08
NCT07218380
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Trial Treatment · Phase 3 · Eli Lilly and Company
Arthur J.E. Child Comprehensive Cancer Centre, Calgary · Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton · Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus, Québec · BC Cancer - Vancouver, Vancouver
Registry updated 2026-10-07
NCT04574960
Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)
Trial Treatment · Phase 3 · University Health Network, Toronto
The Ottawa Hospital, Ottawa · University Health Network, Toronto
Registry updated 2026-10-06
NCT06833073
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Trial Treatment · Phase 2 · Merck Sharp & Dohme LLC
The Moncton Hospital-Oncology ( Site 0200), Moncton · Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0204), Sherbrooke
Registry updated 2026-10-01
NCT07346053
The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder Cancer
Trial Treatment · Phase 3 · Guliz Ozgun
BC Cancer Abbotsford, Abbotsford British Columbia · BC Cancer ? Kelowna (Sindi Ahluwalia Hawkins Centre), Kelowna · BC Cancer Surrey, Surrey · BC Cancer - Vancouver Cancer Centre, Vancouver · BC Cancer - Victoria, Victoria
Registry updated 2026-10-01
NCT05562830
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
Trial Treatment · Phase 1/2 · Merck Sharp & Dohme LLC
Princess Margaret Cancer Centre ( Site 1106), Toronto
Registry updated 2026-09-28
NCT06567743
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Trial Treatment · Phase 2 · CG Oncology, Inc.
Centre of Applied Urology Research/Nova Scotia Health Authority, Halifax
Registry updated 2026-09-03
NCT05951179
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Trial Treatment · Phase 2 · Protara Therapeutics
Exdeo Clinical Research Inc, Abbotsford British Columbia · Jonathan Giddes Medicine Professional Corporation, Brampton · The Research Institute of the McGill University Health Centre, Montreal · UHN Princess Margaret Cancer Centre Princess Margaret Hospital, Toronto · Sunnybrook Research Institute, Toronto
Registry updated 2026-08-24
NCT04895709
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Trial Treatment · Phase 1/2 · Bristol-Myers Squibb
Cross Cancer Institute, Edmonton · Hamilton Health Sciences-Juravinski Cancer Centre, Hamilton · Centre Hospitalier de luniversite de Montreal, Montreal · Ottawa · Toronto · Vancouver
Registry updated 2026-08-17

All Bladder cancer trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error